## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Insulin aspart (Novolog®)

<u>Initiation (new start) criteria</u>: Non-formulary insulin aspart (Novolog) or its unbranded biologic (insulin aspart) will be covered on the prescription drug benefit when the following criteria are met:

 Diagnosis of Type 2 diabetes mellitus with a documented allergy or intolerance\* to regular insulin AND insulin lispro

## -OR-

• Diagnosis of Type 1 diabetes mellitus or Type 2 diabetes mellitus with insulinopenia<sup>^</sup> with a documented allergy or intolerance<sup>\*</sup> to insulin lispro

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary **insulin aspart**(Novolog) or its unbranded biologic (insulin aspart) will be covered on the prescription drug benefit when the following criteria are met:


 Diagnosis of Type 2 diabetes mellitus with a documented allergy or intolerance\* to regular insulin AND insulin lispro

## -OR-

 Diagnosis of Type 1 diabetes mellitus or Type 2 diabetes mellitus with insulinopenia<sup>^</sup> with a documented allergy or intolerance<sup>\*</sup> to insulin lispro

kp.org

Revised: 04/14/22 Effective: 06/02/22





<sup>\*</sup> Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

<sup>^</sup> Insulinopenia is defined as a fasting c-peptide level of 0.88 ng/mL or less with a concurrent glucose of 70-225 mg/dL OR in patients with renal insufficiency (creatinine clearance of 50 mL/min or less), a fasting c-peptide level of 1.6 ng/mL or less with a concurrent glucose of 70-225 mg/dL.